Healthy Returns: 1 in 8 adults have taken Ozempic or other GLP-1s, survey says
Publishing timestamp: 2024-05-14 15:58:11
Summary
The use of GLP-1 drugs for weight loss and diabetes treatment is on the rise in the U.S. despite high costs and limited insurance coverage. A survey shows that a significant number of Americans are taking these drugs, with differences in usage based on race, ethnicity, and age. Additionally, Google has announced a new artificial intelligence model called AlphaFold 3, which aims to transform drug discovery and biological research by predicting the shapes and behaviors of various molecules.
Sentiment: NEUTRAL
Tickers: GOOGL, NVO, LLY, NOVO.B-DK,
Keywords: biotech and pharmaceuticals, alphabet inc, social issues, health care industry, science, united states, eli lilly and co, novo nordisk a/s, business news, artificial intelligence, weight management,